Portal de Periódicos da CAPES

CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease

2023; Elsevier BV; Volume: 23; Issue: 10 Linguagem: Inglês

10.1016/j.clml.2023.05.007

2152-2650

Uroosa Ibrahim, Claude Bassil, Julio C. Chávez, Farhad Khimani, Michael D. Jain, Frederick L. Locke, Keren Osman, Aleksandr Lazaryan,

Viral Infectious Diseases and Gene Expression in Insects

•CAR T cell therapy can be a safe an effective treatment option for post-transplant lymphoproliferative disorder. •Careful management of immunosuppressive medications before and during the treatment period is required to prevent graft rejection. •Low dose of immunosuppression during CAR T cell therapy can be maintained and may not affect efficacy. •A multidisciplinary team approach throughout the process is essential. •CAR T cell therapy can be a safe an effective treatment option for post-transplant lymphoproliferative disorder. •Careful management of immunosuppressive medications before and during the treatment period is required to prevent graft rejection. •Low dose of immunosuppression during CAR T cell therapy can be maintained and may not affect efficacy. •A multidisciplinary team approach throughout the process is essential.